Last reviewed · How we verify
Botox-Tend
Botox-Tend is a botulinum toxin-based therapeutic designed to reduce muscle tension and improve tendon function through localized neuromuscular blockade.
Botox-Tend is a botulinum toxin-based therapeutic designed to reduce muscle tension and improve tendon function through localized neuromuscular blockade. Used for Tendon disorders with associated muscle hyperactivity (specific indication under investigation in phase 3).
At a glance
| Generic name | Botox-Tend |
|---|---|
| Also known as | onabotulinumtoxinA |
| Sponsor | National Cheng-Kung University Hospital |
| Drug class | Botulinum toxin derivative |
| Target | Acetylcholine release at neuromuscular junction (SNARE complex) |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Musculoskeletal |
| Phase | Phase 3 |
Mechanism of action
The drug likely works by inhibiting acetylcholine release at the neuromuscular junction, reducing muscle hyperactivity and spasticity around affected tendons. This mechanism may alleviate pain, improve mobility, and promote healing in tendon-related pathologies by decreasing abnormal muscle tension and load on the affected tissue.
Approved indications
- Tendon disorders with associated muscle hyperactivity (specific indication under investigation in phase 3)
Common side effects
- Muscle weakness
- Pain at injection site
- Localized hematoma
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botox-Tend CI brief — competitive landscape report
- Botox-Tend updates RSS · CI watch RSS
- National Cheng-Kung University Hospital portfolio CI